{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:32:13Z","timestamp":1789590733504,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:38:26Z","timestamp":1771274306000},"page":"710-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0013-5098","authenticated-orcid":false,"given":"Maike K.","family":"Klett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"Lakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma Q.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Serzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Karger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.01.012_b0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen","volume":"12","author":"Vickers","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.euo.2026.01.012_b0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen\u2013based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European Randomised Study of Screening for Prostate Cancer","volume":"84","author":"de Vos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.01.012_b0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2021.12.011","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort","volume":"82","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdr056","article-title":"Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer","volume":"23","author":"Brandt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41391-022-00609-3","article-title":"Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine","volume":"26","author":"Marino","year":"2023","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.012_b0045","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.012_b0050","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","article-title":"Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants","volume":"55","author":"Wang","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2026.01.012_b0055","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/s41467-025-57312-9","article-title":"Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men","volume":"16","author":"Gong","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.01.012_b0060","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1038\/s41467-023-43726-w","article-title":"Prostate cancer genetic risk and associated aggressive disease in men of African ancestry","volume":"14","author":"Soh","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.01.012_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.01.012_b0070","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12885-024-12388-2","article-title":"The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and Bayesian network meta-analysis","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0080","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.012_b0085","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0090","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.19.02808","article-title":"Risk of prostate cancer associated with familial and hereditary cancer syndromes","volume":"38","author":"Beebe-Dimmer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0095","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-18-0370","article-title":"Family history of breast or prostate cancer and prostate cancer risk","volume":"24","author":"Barber","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.012_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003616","article-title":"Risk of prostate cancer in relatives of prostate cancer patients in Sweden: a nationwide cohort study","volume":"18","author":"Xu","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2026.01.012_b0105","series-title":"PDQ genetics of prostate cancer","author":"PDQ Cancer Genetics Editorial Board","year":"2025"},{"key":"10.1016\/j.euo.2026.01.012_b0110","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate","author":"Daly","year":"2025"},{"key":"10.1016\/j.euo.2026.01.012_b0115","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.012_b0125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.012_b0140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0145","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2026.01.012_b0160","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang Y, Stopsack KH, et al. Identifying patients at risk of early lethal prostate cancer by integrating family history, polygenic risk score, rare variants in DNA repair genes, and lifestyle factors. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2025.03.008.","DOI":"10.1016\/j.euo.2025.03.008"},{"issue":"1","key":"10.1016\/j.euo.2026.01.012_b0165","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.01.012_b0170","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.01.012_b0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41391-018-0083-4","article-title":"Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer","volume":"22","author":"Krimphove","year":"2019","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.012_b0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2022.03.007","article-title":"Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care","volume":"82","author":"Nyame","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.012_b0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","article-title":"Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European","volume":"18","author":"Ndugga-Kabuye","year":"2019","journal-title":"Fam Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39571","article-title":"rates and classification of variants of uncertain significance in hereditary disease genetic testing","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.01.012_b0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/UPJ.0000000000000352","article-title":"perceptions, and use of cancer-based genetic testing among healthy U.S. adults and those with prostate or breast\/ovarian cancer","volume":"10","author":"Thakker","year":"2023","journal-title":"Urol Pract"},{"key":"10.1016\/j.euo.2026.01.012_b0200","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaoncol.2018.0340","article-title":"National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer","volume":"4","author":"Childers","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4143\/crt.2020.364","article-title":"Uptake of family-specific mutation genetic testing among relatives of patients with ovarian cancer with BRCA1 or BRCA2 mutation","volume":"53","author":"Jeong","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euo.2026.01.012_b0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers","volume":"7","author":"Hage Chehade","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.01.012_b0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10897-008-9183-y","article-title":"The impact of social roles on the experience of men in BRCA1\/2 families: implications for counseling","volume":"18","author":"Daly","year":"2009","journal-title":"J Genet Counsel"},{"key":"10.1016\/j.euo.2026.01.012_b0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jwh.2011.2876","article-title":"Gender differences in utilization of preventive care services in the United States","volume":"21","author":"Vaidya","year":"2012","journal-title":"J Womens Health"},{"key":"10.1016\/j.euo.2026.01.012_b0225","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jadohealth.2022.09.031","article-title":"Gender differences in routine health maintenance examinations before and during the COVID-19 pandemic","volume":"72","author":"Vargas","year":"2023","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.euo.2026.01.012_b0230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2016.07.023","article-title":"Barriers and facilitators to health screening in men: a systematic review","volume":"165","author":"Teo","year":"2016","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.euo.2026.01.012_b0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10689-013-9609-z","article-title":"Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial","volume":"12","author":"Montgomery","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0240","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10689-016-9889-1","article-title":"Communicating genetic test results within the family: is it lost in translation? A survey of relatives in the randomized six-step study","volume":"15","author":"Daly","year":"2016","journal-title":"Fam Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0245","doi-asserted-by":"crossref","first-page":"20178","DOI":"10.1038\/s41598-021-98737-8","article-title":"Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design","volume":"11","author":"Blomen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.01.012_b0250","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pec.2017.07.015","article-title":"\u201cI\u2019ve just never gotten around to doing it\u201d: Men\u2019s approaches to managing BRCA-related cancer risks","volume":"101","author":"Rauscher","year":"2018","journal-title":"Patient Educ Counsel"},{"key":"10.1016\/j.euo.2026.01.012_b0255","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10689-011-9425-2","article-title":"BRCA1\/2 genetic testing uptake and psychosocial outcomes in men","volume":"10","author":"Graves","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0260","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clinbiochem.2014.08.006","article-title":"Association of sociodemographic factors and prostate-specific antigen (PSA) testing","volume":"47","author":"Gorday","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.euo.2026.01.012_b0265","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamainternmed.2017.0340","article-title":"Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States","volume":"177","author":"Fedewa","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euo.2026.01.012_b0270","unstructured":"Leitlinienprogramm Onkologie. S3-Leitlinie Prostatakarzinom, Langversion 8.0. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom."},{"key":"10.1016\/j.euo.2026.01.012_b0275","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Cornford","year":"2025"},{"key":"10.1016\/j.euo.2026.01.012_b0280","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bju.16432","article-title":"The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers","volume":"134","author":"Bancroft","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.01.012_b0285","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bju.14412","article-title":"Psychosocial impact of undergoing prostate cancer screening for men with BRCA 1 or BRCA 2 mutations","volume":"123","author":"Bancroft","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.01.012_b0290","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pon.5831","article-title":"Coping response and family communication of cancer risk in men harboring a BRCA mutation: a mixed methods study","volume":"31","author":"Dwyer","year":"2022","journal-title":"Psycho-Oncology"},{"key":"10.1016\/j.euo.2026.01.012_b0295","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.01.012_b0300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12916-022-02291-7","article-title":"An international consensus on the essential and desirable criteria for an \u2018organized\u2019 cancer screening programme","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.euo.2026.01.012_b0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41436-018-0020-x","article-title":"Validation of version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST\u2122)","volume":"21","author":"Bellcross","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2026.01.012_b0310","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.clgc.2021.11.009","article-title":"Helix: a digital tool to address provider needs for prostate cancer genetic testing in clinical practice","volume":"20","author":"Giri","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0315","unstructured":"National Cancer Institute. Speaking with your family. https:\/\/ccr.cancer.gov\/surgical-oncology-program\/clinical-team\/speaking-with-your-family."},{"key":"10.1016\/j.euo.2026.01.012_b0320","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1186\/s12885-022-10429-2","article-title":"Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study","volume":"22","author":"Vlaming","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2026.01.012_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106821","article-title":"Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing","volume":"119","author":"Loeb","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euo.2026.01.012_b0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.01.012_b0335","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19284","volume":"3","author":"Kovac","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.01.012_b0340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study","volume":"7","author":"Eldred-Evans","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0345","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41591-023-02277-9","article-title":"Genetically adjusted PSA levels for prostate cancer screening","volume":"29","author":"Kachuri","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.01.012_b0350","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): prostate cancer early detection","author":"Moses","year":"2025"},{"key":"10.1016\/j.euo.2026.01.012_b0355","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41391-025-00938-z","article-title":"Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1\/2 variants","volume":"28","author":"Stroomberg","year":"2025","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.012_b0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2025.12.018","article-title":"Genetic testing and imaging in men with familial history or genetic predisposition of prostate cancer\u2014introducing the prospective \u201cProFam-Risk\u201d study","volume":"84","author":"Lakes","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.01.012_b0365","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","article-title":"Digital rectal examination is not a useful screening test for prostate cancer","volume":"6","author":"Krilaviciute","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0370","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European model for an organised risk-stratified early detection programme for prostate cancer","volume":"4","author":"Van Poppel","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.012_b0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.eururo.2020.12.010","article-title":"Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission","volume":"79","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:42:09Z","timestamp":1783197729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126000362"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}